Literature DB >> 26391283

Measuring motivation in people with schizophrenia.

Gagan Fervaha1, George Foussias2, Hiroyoshi Takeuchi3, Ofer Agid2, Gary Remington2.   

Abstract

Motivational deficits are a key determinant of poor functional outcomes in schizophrenia. These impairments are typically evaluated using various clinical rating scales; however, the degree of convergence between motivation scores derived from different instruments is not clear. In the present study, we measured motivational deficits in 62 patients with schizophrenia using 5 scores derived from 3 different instruments. We found that the scores from these different instruments were highly inter-correlated, and largely independent of severity of other symptom domains (e.g., depression). Our findings suggest that clinical ratings scales evaluating motivational deficits are tapping into a similar underlying construct.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amotivation; Apathy; Avolition; Negative symptoms; Psychosis; Schizophrenia

Mesh:

Year:  2015        PMID: 26391283     DOI: 10.1016/j.schres.2015.09.012

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.

Authors:  Gagan Fervaha; Fernando Caravaggio; David C Mamo; Benoit H Mulsant; Bruce G Pollock; Shinichiro Nakajima; Philip Gerretsen; Tarek K Rajji; Wanna Mar; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Gary Remington; Ariel Graff-Guerrero
Journal:  Psychopharmacology (Berl)       Date:  2016-08-24       Impact factor: 4.530

2.  Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia.

Authors:  Daniel R Garton; Ana R Montaño-Rodríguez; Soophie Olfat; Kärt Mätlik; Feride Eren; Laoise Casserly; Anastasios Damdimopoulos; Anne Panhelainen; L Lauriina Porokuokka; Jaakko J Kopra; Giorgio Turconi; Nadine Schweizer; Erika Bereczki; Fredrik Piehl; Göran Engberg; Simon Cervenka; T Petteri Piepponen; Fu-Ping Zhang; Petra Sipilä; Johan Jakobsson; Carl M Sellgren; Sophie Erhardt; Jaan-Olle Andressoo
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 15.992

Review 3.  A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors:  Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Clin Psychol Rev       Date:  2018-04-07

4.  Relationship between effortful motivation and neurocognition in schizophrenia.

Authors:  Andrew W Bismark; Michael L Thomas; Melissa Tarasenko; Alexandra L Shiluk; Sonia Y Rackelmann; Jared W Young; Gregory A Light
Journal:  Schizophr Res       Date:  2017-06-30       Impact factor: 4.939

Review 5.  Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development.

Authors:  Gregory P Strauss; Lisa A Bartolomeo; Philip D Harvey
Journal:  NPJ Schizophr       Date:  2021-02-26

6.  EPA guidance on assessment of negative symptoms in schizophrenia.

Authors:  S Galderisi; A Mucci; S Dollfus; M Nordentoft; P Falkai; S Kaiser; G M Giordano; A Vandevelde; M Ø Nielsen; L B Glenthøj; M Sabé; P Pezzella; I Bitter; W Gaebel
Journal:  Eur Psychiatry       Date:  2021-02-18       Impact factor: 5.361

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.